While overdoses remain the largest cause of death in opioid users there are other causes which providers, commissioners and policy makers need to be conscious of particularly amongst older drug users, including liver disease, smoking related diseases, homicide and suicide.
11 hours ago | DrugScope
Greece's left-wing Syriza party looks set to win the country's upcoming election on the platform of alleviating the economic crisis that has brought Greece to its knees and stoked an HIV epidemic among drug users. Could this mark a turning point for harm reduction services and marginalized groups?
26 January 2015 | Talking Drugs
HIV is spreading at a dangerous rate in nations around the Black Sea, passing a record 100,000 new cases yearly. Hotspots for the HIV rise are Ukraine and Russia - two countries facing economic crisis and armed conflict, factors which could provoke a further surge in the virus.
26 January 2015 | EUobserver
As many as 100 drug users in Crimea may have died since the peninsula was annexed by Russia, according to a top UN official, due to fact that the “substitution therapy” they were receiving from Ukrainian authorities being illegal under Russian law.
23 January 2015 | The Guardian
Can naloxone provided in the community help reduce the thousands of drug-induced deaths recorded in Europe every year? This is the question explored by the EU drugs agency (EMCDDA) in a new paper released today: Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone.
20 January 2015 | European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Often viewed as one of the most telltale signs of a true "junkie," there is no doubt about the stigma that comes with track marks.
16 January 2015 | Talking Drugs
AbbVie has issued its guidance for 2015, and that guidance suggests that its newly launched hepatitis C drug cocktail, Viekira Pak, could be a big driver of earnings growth this year. In December, Viekira Pak received FDA approval as a treatment for hepatitis C genotype 1 after delivering compelling functional cure rates in the mid-90% range during clinical trials. That approval was highly anticipated by health care payers desperate for competition in this market, because hepatitis C market share leader Gilead Sciences' two hepatitis C drugs, Sovaldi and Harvoni, carry eye-popping price tags that are translating into billions of additional dollars in health care spending.
15 January 2015 | The Motley Fool
Public Health England cautions that the gains of recent years in reduced drug use, lower demand for treatment for heroin and crack problems, improved treatment performance, and curbing drug-related harm, have all stalled or gone in to reverse. It might be a blip, or might prove to be the start of a trend up in problem drug use and down in the ability of the treatment system to cope. Includes new five-year treatment journey analysis.
09 January 2015 | Drug & Alcohol Findings
In the past year Uganda has passed four laws which defy public health principles and show blatant disregard for dignity and human rights. These laws target individuals who are already marginalized by society and most in need of health services and support: people who sell sex to make ends meet for their families; LGBTI people living in fear of community violence; people hiding their HIV medication from their own families; and people struggling to manage drug dependence and other illnesses. Perhaps most harmful of all, parts of Ugandan society are interpreting these laws to justify violence and exclusion.
17 December 2014 | Open Society Foundation
Occasional heroin use by HIV-positive patients may be particularly harmful to the immune system and worsens HIV disease, compared to persistent or no heroin use, an international team of researchers reports.
17 December 2014 | Science Daily